Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients.

ABSTRACT:

Background

Evidence on safety and effectiveness of omalizumab for treatment of chronic urticaria in pediatric patients is scarce and limited to case reports. In particular, drug survival of omalizumab has not yet been investigated, which is a key element in the evaluation of its clinical performance. The aim of this study was to investigate safety, effectiveness, and drug survival rates of omalizumab in a daily practice cohort of pediatric patients with chronic urticaria (CU).

Methods

This is a multicenter study including all pediatric patients from an academic center (Wilhelmina Children's Hospital) and a general center (Diakonessenhuis Hospital) in the Netherlands, who started omalizumab treatment before the age of 18 years. Data on safety, effectiveness, time to discontin

SUBMITTER: Dekkers C 

PROVIDER: S-EPMC8248194 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature